FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					_									_					
Name and Address of Reporting Person* Schroeder Theodore R					<u>CC</u>	2. Issuer Name and Ticker or Trading Symbol COLLEGIUM PHARMACEUTICAL, INC							(Ch	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
,	[C	[COLL]									_	(give title		Other (s					
(Last)	(Fi	irst)	(Middle)		2 D	O. Data of Farliant Transaction (Marsh/DavNess)								\dashv	below)			below)	specify
780 DEDHAM STREET, SUITE 800						3. Date of Earliest Transaction (Month/Day/Year) 06/09/2016													
(Street)				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
CANTON MA 02021														X Form filed by One Reporting Person				n	
(City) (State) (Zip)														Form filed by More than One Reporting Person				rting	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of S	Security (Ins	tr. 3)		2. Transa	action	7	2A. Deem	ed	3.		4. Securi	ities Acqu	ired (A) or	5. Amou	nt of	6. Ov	vnership	7. Nature
Date				Execution Date, if any (Month/Day/Year)			Transac Code (I	Transaction Disposed Of (D) (Instr. 3, Code (Instr. 5)				Securition Benefici	rities I ficially (ed Following (n: Direct r Indirect istr. 4)	of Indirect Beneficial Ownership			
									Code	v	Amount	(A) (D)	(A) or (D) Price		Reporte Transac (Instr. 3	ction(s)			(Instr. 4)
		7	able II - D						uired, Di , option						Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		n of E		Expiration	5. Date Exercisable and Expiration Date Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Owners Form: Iy Direct (or Indir	Ownership	Beneficial Ownership ect (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	or Nu of	ımber					
Stock Option (Right to Purchase)	\$16.49	06/09/2016			A		8,700		(1)	00	6/09/2026	Common Stock	8	,700	\$0	8,700		D	

Explanation of Responses:

1. The option vests and becomes exercisable on June 9, 2017, subject to the director's continued service with the issuer.

Remarks:

/s/ Paul Brannelly as Attorney-In-Fact For Theodore R. 06/13/2016 Schroeder

** Signature of Reporting Person Date

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.